detectability of uncommon egfr mutations in nsclc: ngs versus pcr
Published 2 years ago • 196 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:04
ngs provides improved identification of uncommon egfr mutations over pcr in nsclc
-
0:42
ngs vs pcr for egfr genotyping in nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
3:37
next generation sequencing in lung cancer
-
3:38
studies on egfr mutants in nsclc
-
4:06
afatinib in patients with uncommon egfr mutations
-
1:04
molecular testing in egfr mutant driven nsclc
-
39:35
egfr mutation analysis
-
5:34
rare egfr mutations in lung adenocarcinoma
-
22:49
grace targeted therapies lung cancer 2021 - management of uncommon egfr mutations including exon 20
-
1:05
advances in managing krasg12c- and egfr-mutated nsclc
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
12:23
clinical clips: spotlighting hot topics in nsclc harboring egfr mutations
-
43:43
webinar: going beyond egfr: evaluating technologies for molecular genetic testing in nsclc